UK markets close in 6 hours 29 minutes
  • FTSE 100

    7,086.61
    +12.55 (+0.18%)
     
  • FTSE 250

    22,635.45
    -23.97 (-0.11%)
     
  • AIM

    1,231.77
    +0.68 (+0.06%)
     
  • GBP/EUR

    1.1713
    +0.0012 (+0.10%)
     
  • GBP/USD

    1.3971
    +0.0007 (+0.05%)
     
  • BTC-GBP

    23,893.76
    -391.14 (-1.61%)
     
  • CMC Crypto 200

    807.33
    -2.87 (-0.35%)
     
  • S&P 500

    4,241.84
    -4.60 (-0.11%)
     
  • DOW

    33,874.24
    -71.34 (-0.21%)
     
  • CRUDE OIL

    73.49
    +0.41 (+0.56%)
     
  • GOLD FUTURES

    1,781.50
    -1.90 (-0.11%)
     
  • NIKKEI 225

    28,875.23
    +0.34 (+0.00%)
     
  • HANG SENG

    28,882.46
    +65.39 (+0.23%)
     
  • DAX

    15,563.96
    +107.57 (+0.70%)
     
  • CAC 40

    6,607.21
    +56.14 (+0.86%)
     

Pharvaris Announces Annual Meeting of Shareholders

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.

ZUG, Switzerland, June 11, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the annual general meeting of shareholders will take place on Tuesday, June 29, 2021 at 1:00 p.m. CEST (7:00 a.m. EDT).

All relevant documents and information relating to the annual general meeting, including the notice and agenda for the annual general meeting, are or will be made available in the “Investors” section of Pharvaris’ website under “Events & Presentations”. The documents will also be made available on the SEC’s website at www.sec.gov. Shareholders who wish to attend the meeting should register as described in the notice and agenda for the annual general meeting.

About Pharvaris
Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The Company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. For more information, visit https://pharvaris.com/.

Investor Contact
Sarah McCabe
Stern Investor Relations, Inc.
+1-212-362-1200
sarah.mccabe@sternir.com

Media Contact
Maggie Beller
Russo Partners, LLC
+1-646-942-5631
maggie.beller@russopartnersllc.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting